Correction: Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia (PLoS ONE (2014) 9, 2 (e87210) DOI: 10.1371/journal.pone.0087210);Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Terme, Mickaël ^a   Dorvillius, Mylène ^a   Cochonneau, Denis ^a   Chaumette, Tanguy ^a,f   Xiao, Wenhua ^b   Diccianni, Mitchell B ^c   Barbet, Jacques ^a   Yu, Alice L ^c,d   Paris, François ^a   Sorkin, Linda S ^e   Birklé, Stéphane ^a,f  

^a UNIVERSITÉ DE NANTES   (France)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e University of California   (United States)

^f UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; CHIMERIC ANTIBODY C 8B6; GANGLIOSIDE GD2; MONOCLONAL ANTIBODY CH14 18; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; IMMUNOGENICITY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; MALE; MOUSE; NERVE FIBER; NEUROBLASTOMA; NONHUMAN; RAT;

ACETYLATION; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; FLOW CYTOMETRY; GANGLIOSIDES; HUMANS; HYPERALGESIA; INJECTIONS, INTRAVENOUS; MICE; NEUROBLASTOMA; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84895759475     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103395     Document Type: Erratum

References (48)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369: 2106-2120. (Pubitemid 46935947)
2. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, et al. (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 27: 1007-1013.
3. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, et al. (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363: 1324-1334.
4. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, et al. (1991) Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 51: 144-149.
5. Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, et al. (1987) Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5: 1430-1440. (Pubitemid 18049879)
6. Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, et al. (1992) A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 35: 199-204.
7. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, et al. (1992) Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 52: 4342-4347.
8. Yuki N, Yamada M, Tagawa Y, Takahashi H, Handa S (1997) Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy. J Neurol Sci 149: 127-130. (Pubitemid 27202367)
9. Sorkin LS, Otto M, Baldwin WM 3rd, Vail E, Gillies SD, et al. (2010) Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain 149: 135-142.
10. Kushner BH, Kramer K, Modak S, Cheung NK (2011) Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. J Clin Oncol 29: 1168-1174.
11. Cerato E, Birkle S, Portoukalian J, Mezazigh A, Chatal JF, et al. (1997) Variable region gene segments of nine monoclonal antibodies specific to disialoganglio-sides (GD2, GD3) and their O-acetylated derivatives. Hybridoma 16: 307-316. (Pubitemid 27410599)
12. Sjoberg ER, Manzi AE, Khoo KH, Dell A, Varki A (1992) Structural and immunological characterization of O-acetylated GD2. Evidence that GD2 is an acceptor for ganglioside O-acetyltransferase in human melanoma cells. J Biol Chem 267: 16200-16211.
13. Ye JN, Cheung NK (1992) A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies. Int J Cancer 50: 197-201.
14. Alvarez-Rueda N, Desselle A, Cochonneau D, Chaumette T, Clemenceau B, et al. (2011) A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity. PLoS One 6: e25220.
15. Khazaeli MB, Saleh MN, Wheeler RH, Huster WJ, Holden H, et al. (1988) Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J Natl Cancer Inst 80: 937-942.
16. Vincent M, Bessard A, Cochonneau D, Teppaz G, Sole V, et al. (2013) Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. Int J Cancer 133: 757-765.
17. Alvarez-Rueda N, Leprieur S, Clemenceau B, Supiot S, Sebille-Rivain V, et al. (2007) Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen. Clin Cancer Res 13: 5613s-5620s. (Pubitemid 47510395)
18. Bouchon B, Portoukalian J, Madec AM, Orgiazzi J (1990) Evidence for several cell populations in human thyroid with distinct glycosphingolipid patterns. Biochim Biophys Acta 1051: 1-5. (Pubitemid 20043379)
19. Popa I, Vlad C, Bodennec J, Portoukalian J (2002) Recovery of gangliosides from aqueous solutions on styrene-divinylbenzene copolymer columns. J Lipid Res 43: 1335-1340. (Pubitemid 34988181)
20. Svennerholm L (1963) Chromatographic Separation of Human Brain Gangliosides. J Neurochem 10: 613-623.
21. Raguin O, Gruaz-Guyon A, Barbet J (2002) Equilibrium expert: an add-in to Microsoft Excel for multiple binding equilibrium simulations and parameter estimations. Anal Biochem 310: 1-14. (Pubitemid 35387325)
22. Wilkinson RW, Lee-MacAry AE, Davies D, Snary D, Ross EL (2001) Antibody-dependent cell-mediated cytotoxicity: a flow cytometry-based assay using fluorophores. J Immunol Methods 258: 183-191. (Pubitemid 33016538)
23. Clemenceau B, Gallot G, Vivien R, Gaschet J, Campone M, et al. (2006) Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy. J Immunother 29: 53-60.
24. Sjogren HO, Hellstrom I (1965) Induction of polyoma specific transplantation antigenicity in Moloney leukemia cells. Exp Cell Res 40: 208-212.
25. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, et al. (1997) Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 89: 1586-1594. (Pubitemid 27479718)
26. Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, et al. (2005) Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 42: 1311-1319. (Pubitemid 40798947)
27. Slart R, Yu AL, Yaksh TL, Sorkin LS (1997) An animal model of pain produced by systemic administration of an immunotherapeutic anti-ganglioside antibody. Pain 69: 119-125. (Pubitemid 27081416)
28. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63. (Pubitemid 24238751)
29. Dixon WJ (1980) Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20: 441-462.
30. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, et al. (1984) Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44: 5914-5920. (Pubitemid 15183611)
31. Wallace MS, Lee J, Sorkin L, Dunn JS, Yaksh T, et al. (1997) Intravenous lidocaine: effects on controlling pain after anti-GD2 antibody therapy in children with neuroblastoma-a report of a series. Anesth Analg 85: 794-796. (Pubitemid 27418881)
32. Xiao WH, Yu AL, Sorkin LS (1997) Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody. Pain 69: 145-151. (Pubitemid 27081420)
33. Cheresh DA, Rosenberg J, Mujoo K, Hirschowitz L, Reisfeld RA (1986) Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res 46: 5112-5118. (Pubitemid 16008275)
34. Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, et al. (1989) Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 49: 2857-2861. (Pubitemid 19148615)
35. Nakamura K, Tanaka Y, Shitara K, Hanai N (2001) Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions. Cancer Immunol Immunother 50: 275-284. (Pubitemid 32662531)
36. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, et al. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99: 754-758. (Pubitemid 34525533)
37. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, et al. (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10: 5650-5655. (Pubitemid 39180938)
38. Taylor RJ, Chan SL, Wood A, Voskens CJ, Wolf JS, et al. (2009) FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 58: 997-1006.
39. Louis E, El Ghoul Z, Vermeire S, Dall'Ozzo S, Rutgeerts P, et al. (2004) Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 19: 511-519. (Pubitemid 38387177)
40. Ahmed M, Goldgur Y, Hu J, Guo HF, Cheung NK (2013) In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors. PLoS One 8: e63359.
41. Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, et al. (1988) Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci U S A 85: 4852-4856.
42. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, et al. (2004) Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 279: 6213-6216. (Pubitemid 38248752)
43. Imai M, Landen C, Ohta R, Cheung NK, Tomlinson S (2005) Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res 65: 10562-10568. (Pubitemid 41743751)
44. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, et al. (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 111: 5486-5495.
45. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, et al. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177: 362-371. (Pubitemid 43939148)
46. Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY (2012) Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 1: 477-486.
47. Aixinjueluo W, Furukawa K, Zhang Q, Hamamura K, Tokuda N, et al. (2005) Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J Biol Chem 280: 29828-29836. (Pubitemid 41179010)
48. Cochonneau D, Terme M, Michaud A, Dorvillius M, Gautier N, et al. (2013) Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo. Cancer Lett 333: 194-204.